Global Alopecia Areata Market
The global alopecia areata market is expected to reach USD 17,933.92 million by 2031 from USD 9,582.20 million in 2023, growing with a CAGR of 8.1% in the forecast period of 2024 to 2031.
Market Segmentation:
Global Alopecia Areata Market, By Disease Type (Alopecia Areata (Patchy), Alopecia Areata Totalis, Alopecia Areata Universalis, and Others), Cause (Non-Genetic and Genetic), Type (Treatment and Diagnosis), Age Group (Below 18 Years, 18-50 Years, and Above 50 Years), Gender (Female and Male), Country (U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, rest of Europe, Japan, China, South Korea, Australia, India, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, rest of Asia-Pacific, Brazil, Argentina, Peru, rest of South America, Saudi Arabia, South Africa, U.A.E., Kuwait, Israel, Egypt, and rest of Middle East and Africa) - Industry Trends and Forecast to 2031
Overview of Global Alopecia Areata Market Dynamics:
Driver
• Increase in geriatric population
Restraint
• Side effects associated with the available hair loss treatment therapies
Opportunity
• Development and technological advancements in hair treatment medical devices
Market Players:
The key market players operating in the global alopecia areata market are listed below:
• Pfizer Inc.
• Dr. Reddy's Laboratories Ltd.
• Lilly
• Sun Pharmaceutical Industries Ltd.
• GSK plc.
• Johnson & Johnson Consumer Inc.
• Lupin
• Croma-Pharma GmbH
• Viviscal Limited (A Subsidiary of Church & Dwight Co.)
• AdvaCare Pharma
• Wellona Pharma
• Teva Pharmaceuticals USA, Inc.
• Croma-Pharma GmbH
• Follicum AB
• Nanogen
• Vitabiotics Ltd.
• Reistone Biopharma
• TechnoDerma Medicines Inc.
Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions. This publisher does offer titles that are created upon receipt of order.